Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Juan José Valerdi álvarez"'
Autor:
Maite Martínez Aguillo, M. Gutiérrez, Francisco Javier Domínguez del Valle, Enrique Martínez López, Juan José Albistur Tomé, Elena Pruja Arteaga, Juan José Valerdi Álvarez
Publikováno v:
Clinical and Translational Oncology. 6:219-223
Introduction Since the decade of the 80's, the etoposide plus cisplatinum regimen has been the standard treatment in patients with localised small-cell lung cancer (SCLC). Randomised trials have demonstrated the benefit of chemotherapy in combination
Autor:
Ruth Vera García, M. Gutiérrez, Juan José Valerdi Álvarez, Fernando Arias de la Vega, Juan José Albistur Tomé, Javier Arellano Aburto, Juan Ignacio Arraras Urdaniz
Publikováno v:
Revista de Oncología. 5:465-470
Introduction The effectiveness of neoadjuvant chemotherapy (Mayo clinic schedule) and continuous oral chemotherapy (tegafur 400 mg and folinic acid 15 mg every 12 hours) administered during preoperative radiotherapy (4,500 cGy over 5 weeks) were stud
Autor:
Ruth Vera García, Begoña Bermejo Fraile, Juan Ignacio Arraras Urdaniz, Juan José Valerdi Álvarez, Francisco Molina Rosillo, Juan José Albistur Tomé, M. Gutiérrez
Publikováno v:
Revista de Oncología. 4:250-254
The main purpose of this prospective non randomized trial was to analyse whether induction chemotherapy and hyperfractionated radiotherapy combined with cisplatin can improve the long-term survival of patients with locally advanced non small cell lun
Autor:
Miguel Ángel Domínguez Domínguez, M. Gutiérrez, Juan José Valerdi Álvarez, Ruth Vera García, Elena Pruja Arteaga, Juan Ignacio Arraras Urdaniz, Marta Marcos Oset, José Juan Illarramendi Mañas
Publikováno v:
Revista de Oncología. 3:100-106
The aim of the present study was to evaluate the quality of life in a sample of breast cancer patients during treatment.